Inside plasma processing: From donor plasma to life-saving therapies Plasma-derived medicinal products (PDMPs) are essential for the treatment of immune deficiencies, coagulation disorders, and critical care conditions. However, their manufacture presents unique challenges due to the biological variability of human plasma, constrained supply, and the complexity of large-scale fractionation and purification processes.
Unlike recombinant systems, plasma processing operates within fixed biological and supply constraints, making process efficiency and recovery central to overall manufacturing performance. In this context, downstream processing plays a critical role in determining yield, product quality, and overall process economics. This article provides an overview of plasma processing, including key stages of fractionation and purification, associated technical hurdles, and the role of chromatography in enabling efficient and scalable manufacturing.
Introduction Plasma-derived therapies remain a cornerstone of modern healthcare, with applications across immunology, hematology, and critical care medicine. Demand for these therapies continues to increase globally, driven by improved diagnosis rates, expanding clinical indications, and aging populations [1]. Plasma-derived products rely on human donor material, making plasma both a valuable and limited resource. Plasma is not simply a raw material, it is a constrained and irreproducible input that ultimately defines the capacity and efficiency of the entire manufacturing process. This introduces unique constraints on manufacturing, requiring processes that maximize recovery while ensuring safety, quality, and regulatory compliance.
The manufacturing process itself is also inherently long and complex, with typical timelines from plasma donation to finished product ranging between 7–12 months. This extended processing cycle further reinforces the need for robust, high-yield operations throughout the process, with downstream efficiency acting as a key determinant of overall manufacturing performance. [4]
Composition and therapeutic value of human plasma Human plasma is a complex biological fluid containing thousands of proteins, many of which have therapeutic relevance. Key proteins include immunoglobulins (IgG), albumin, coagulation factors, and protease inhibitors. The diversity of plasma proteins presents both an opportunity and a complication. While multiple therapies can be derived from a single plasma pool, the complexity of the matrix requires highly selective separation and purification strategies [3]. These proteins often exhibit overlapping physicochemical properties, making selective separation inherently challenging and placing greater reliance on downstream process design. Furthermore, plasma composition varies between donors, necessitating pooling strategies and robust downstream processing to ensure consistent product quality. This variability propagates through fractionation and directly impacts downstream separation performance.
astreabioseparations.com